TA-1801 structure
|
Common Name | TA-1801 | ||
|---|---|---|---|---|
| CAS Number | 88352-44-7 | Molecular Weight | 331.75000 | |
| Density | 1.275g/cm3 | Boiling Point | 471ºC at 760 mmHg | |
| Molecular Formula | C17H14ClNO4 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | 238.6ºC | |
Use of TA-1801TA-1801 is a hypolipidemic agent. |
| Name | ethyl 2-[2-(4-chlorophenyl)-5-(furan-2-yl)-1,3-oxazol-4-yl]acetate |
|---|---|
| Synonym | More Synonyms |
| Description | TA-1801 is a hypolipidemic agent. |
|---|---|
| Related Catalog | |
| In Vitro | TA-1801 inhibits platelet aggregation in vitro[1]. |
| In Vivo | TA-1801 reduces serum cholesterol and triglyceride levels by 23% and 35%, respectively, at a dose of 0.05% in a diet in normal rats, and it is about 10 times more active in hereditary hyperlipidemic rats (THLR/1) than in normal rats[1]. |
| References |
| Density | 1.275g/cm3 |
|---|---|
| Boiling Point | 471ºC at 760 mmHg |
| Molecular Formula | C17H14ClNO4 |
| Molecular Weight | 331.75000 |
| Flash Point | 238.6ºC |
| Exact Mass | 331.06100 |
| PSA | 65.47000 |
| LogP | 4.36060 |
| Index of Refraction | 1.556 |
| Storage condition | 2-8℃ |
|
~83%
TA-1801 CAS#:88352-44-7 |
| Literature: Moriya; Seki; Takabe; Matsumoto; Takashima; Mori; Odawara; Takeyama Journal of Medicinal Chemistry, 1988 , vol. 31, # 6 p. 1197 - 1204 |
|
~%
TA-1801 CAS#:88352-44-7 |
| Literature: Moriya; Seki; Takabe; Matsumoto; Takashima; Mori; Odawara; Takeyama Journal of Medicinal Chemistry, 1988 , vol. 31, # 6 p. 1197 - 1204 |
|
~%
TA-1801 CAS#:88352-44-7 |
| Literature: Moriya; Seki; Takabe; Matsumoto; Takashima; Mori; Odawara; Takeyama Journal of Medicinal Chemistry, 1988 , vol. 31, # 6 p. 1197 - 1204 |
|
~%
TA-1801 CAS#:88352-44-7 |
| Literature: Moriya; Seki; Takabe; Matsumoto; Takashima; Mori; Odawara; Takeyama Journal of Medicinal Chemistry, 1988 , vol. 31, # 6 p. 1197 - 1204 |
| Precursor 3 | |
|---|---|
| DownStream 0 | |
| ta 1801 |
| TA-1801 |